trametinib

Ask MedXY AI

Latest news

Tag

DermatologyBRAF V600-mutant melanomaCOMBI-I trial

Long-Term Survival Benefit of Spartalizumab with Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma: Insights from the COMBI-I Trial

By MedXY|Aug 13, 2026

The COMBI-I trial demonstrates that adding spartalizumab to dabrafenib and trametinib improves overall survival in patients with BRAF V600-mutant advanced melanoma after over 6 years of follow-up, despite not meeting the initial progression

newsovarian cancertrametinib

Biomarker-Driven Precision in Low-Grade Serous Ovarian Cancer: pERK and MAPK Mutations as Predictors of Trametinib Efficacy

By MedXY|Jan 12, 2026

Highlights Background: The Unique Challenge of Low-Grade Serous Ovarian Cancer Low-grade serous ovarian carcinoma (LGSOC)…

Clinical UpdatesanlotinibKRAS mutation

Targeting the MEK/RTK Axis: A Promising Combination Therapy for KRAS-Mutant Non-Small Cell Lung Cancer

By MedXY|Oct 8, 2025

Combining MEK inhibitor trametinib with pan-RTK inhibitor anlotinib shows high efficacy and manageable toxicity in treating advanced non-G12C KRAS-mutant NSCLC, overcoming adaptive resistance and offering improved clinical outcomes.